Health Care·Biotechnology·$79.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $15.37 | N/A | +56.64% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $15.37 | N/A | +56.64% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the earnings per share results, highlighting the strength of their product pipeline. However, they did not provide specific future guidance.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline.
Regeneron's strong EPS performance indicates robust profitability, but the stock's slight decline of 0.69% suggests that investors may have been expecting more comprehensive guidance or revenue details. The lack of revenue data and future guidance could lead to uncertainty among investors moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SIMON PPTY GROUP INC REIT
Nov 1, 2021